About Us

Haorui News | Haorui Genomics and Hong Kong Xcelom Sign Distributorship Agreement to Promote Clinical Testing Products Based on Third‑Generation Sequencing Platforms in Southeast Asia

July 22, 2025, Hong Kong, China.

Haorui Genomics and Xcelom Limited (Xcelom) officially signed a distributorship agreement, authorizing Xcelom to sell and promote Haorui’s third-generation sequencing-based products – including the TransMatch™ HLA genotyping product and blood group genotyping product – in Southeast Asia. The two parties will work together to promote the deployment of a complete thirdgeneration sequencing solution for precision molecular testing in hematology within the region.

Signatories:

Wong Lap Chi, Alex – CEO of Xcelom

Kam Wan Lung, Kenneth Kam – IMD of Xcelom

Bo Wang – General Manager of Haorui

Dai Fu, Zhou – Chairman of Haorui

The signing of this agreement marks the beginning of Haorui’s global push for its molecular diagnostic products. Haorui will provide blood institutions, transplant centers, and clinical laboratories worldwide with an end‑to‑end solution for precise HLA genotyping and blood group genotyping, covering “equipment-reagent kits-reporting software.” Together with its regional distributors, Haorui will also support product technical assistance and local implementation.

About Haorui Genomics

As an innovator in blood group genotyping technology, Haorui Genomics has been committed to driving technological innovation in long‑read sequencing for clinical blood group and related applications since its founding in 2020. Leveraging PacBio’s advanced SMRT HiFi sequencing technology, Haorui has built a central laboratory in Xi’an, China, based on PacBio Sequel II, Revio, and Vega sequencing platforms. This has created a leading development system for third-generation high-throughput sequencing applications in China, offering a new technical platform and more reliable testing products for high-resolution HLA genotyping, blood group genotyping, and rare blood group identification. (Website: www.haoruigenomics.com)

About Xcelom

Xcelom Limited is a biotechnology company focused on medical diagnostics and scientific research. Founded in 2014, it is the exclusive licensee and provider of non-invasive prenatal testing (NIPT) services in Hong Kong. Over the years, Xcelom has expanded from basic prenatal testing to postnatal services and other areas, delivering valuable health information at every stage of life. As an experienced medical diagnostics company with deep roots in the Southeast Asian market, Xcelom not only has a precise grasp of local market conditions, consumer habits, and regulatory policies, but has also built a mature sales network and service system covering major countries in Southeast Asia. (Website: https://www.xcelom.com)